Teacher Retirement System of Texas Acquires 92,643 Shares of DexCom, Inc. $DXCM

Teacher Retirement System of Texas increased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 31.9% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 383,330 shares of the medical device company’s stock after purchasing an additional 92,643 shares during the period. Teacher Retirement System of Texas owned approximately 0.10% of DexCom worth $25,794,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in DXCM. SWS Partners purchased a new stake in DexCom in the second quarter worth about $1,661,000. Jennison Associates LLC raised its position in shares of DexCom by 9.4% in the 2nd quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock worth $1,005,367,000 after acquiring an additional 994,300 shares in the last quarter. Shell Asset Management Co. raised its position in shares of DexCom by 16.8% in the 2nd quarter. Shell Asset Management Co. now owns 35,812 shares of the medical device company’s stock worth $3,126,000 after acquiring an additional 5,138 shares in the last quarter. Marshall Wace LLP lifted its stake in shares of DexCom by 260.7% in the 2nd quarter. Marshall Wace LLP now owns 3,822,085 shares of the medical device company’s stock valued at $333,630,000 after purchasing an additional 2,762,504 shares during the period. Finally, E. Ohman J or Asset Management AB boosted its position in shares of DexCom by 400.2% during the third quarter. E. Ohman J or Asset Management AB now owns 77,492 shares of the medical device company’s stock valued at $5,214,000 after purchasing an additional 62,000 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Down 1.4%

NASDAQ:DXCM opened at $72.86 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.38 and a current ratio of 1.56. The firm has a market cap of $28.42 billion, a P/E ratio of 40.48, a P/E/G ratio of 1.33 and a beta of 1.48. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $93.25. The firm has a 50-day simple moving average of $66.41 and a two-hundred day simple moving average of $71.24.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. The firm had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. DexCom had a net margin of 15.96% and a return on equity of 30.65%. The business’s revenue for the quarter was up 21.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.45 earnings per share. Analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Buying and Selling at DexCom

In other DexCom news, COO Jacob Steven Leach bought 18,200 shares of DexCom stock in a transaction on Monday, November 10th. The stock was acquired at an average price of $55.04 per share, with a total value of $1,001,728.00. Following the acquisition, the chief operating officer owned 331,697 shares in the company, valued at approximately $18,256,602.88. This trade represents a 5.81% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bridgette P. Heller sold 1,012 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total value of $58,766.84. Following the transaction, the director directly owned 27,031 shares in the company, valued at approximately $1,569,690.17. The trade was a 3.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 7,866 shares of company stock worth $448,177. Insiders own 0.32% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Wells Fargo & Company set a $93.00 price objective on DexCom and gave the stock an “overweight” rating in a report on Friday, October 31st. Morgan Stanley reiterated an “overweight” rating on shares of DexCom in a research note on Monday, January 12th. Mizuho lifted their price target on shares of DexCom from $75.00 to $78.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Royal Bank Of Canada cut their price objective on shares of DexCom from $100.00 to $85.00 and set an “outperform” rating on the stock in a report on Friday, October 31st. Finally, Piper Sandler set a $75.00 target price on shares of DexCom and gave the company a “buy” rating in a report on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and an average price target of $86.30.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.